What is the first-line pharmacologic treatment for adult anxiety disorders (e.g., generalized anxiety disorder, panic disorder, social anxiety)?

First-Line Medication for Anxiety Disorders

Selective serotonin reuptake inhibitors (SSRIs)—specifically escitalopram or sertraline—are the recommended first-line pharmacologic treatments for adult anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. 1, 2

Preferred First-Line Agents

Escitalopram and sertraline are the top-tier SSRIs because they demonstrate:

• Established efficacy with moderate-to-high strength evidence 1, 2
• The lowest potential for drug-drug interactions compared to other SSRIs 1
• Minimal discontinuation-symptom burden 1
• Favorable side-effect profiles 1

Dosing Recommendations

For escitalopram: 3

• Start at 10 mg once daily (morning or evening, with or without food)
• May increase to 20 mg after a minimum of one week if needed
• Most patients respond adequately to 10 mg daily

For sertraline: 1, 4

• Start at 25–50 mg once daily
• Titrate by 25–50 mg increments every 1–2 weeks as tolerated
• Target dose: 50–200 mg/day

Expected Timeline for Response

Understanding the response trajectory helps maintain treatment adherence: 1

• Week 2: Statistically significant improvement may begin
• Week 6: Clinically meaningful improvement typically evident
• Week 12 or later: Maximal therapeutic benefit achieved

Do not abandon treatment prematurely—full response requires patience, and the logarithmic response pattern means early gains predict eventual success. 1

Alternative First-Line Options: SNRIs

When SSRIs are ineffective, not tolerated, or based on patient preference, serotonin-norepinephrine reuptake inhibitors (SNRIs) serve as equally valid first-line alternatives: 1, 2

Venlafaxine extended-release: 5, 1

• Dose: 75–225 mg/day
• Effective for generalized anxiety disorder, social anxiety disorder, and panic disorder
• Requires blood pressure monitoring due to risk of sustained hypertension

Duloxetine: 1

• Dose: 60–120 mg/day
• Additional benefits for patients with comorbid pain conditions
• Start at 30 mg daily for one week to reduce nausea

Second-Tier SSRIs (Reserve for First-Line Failures)

Paroxetine and fluvoxamine are equally effective but carry higher risks: 1

• Greater discontinuation symptoms
• More drug-drug interactions
• Should be reserved for cases where escitalopram or sertraline have failed

Critical Safety Considerations

All SSRIs carry a boxed warning for suicidal thinking and behavior: 1

• Pooled absolute risk: 1% versus 0.2% for placebo
• Number needed to harm (NNH): 143
• Monitor closely during the first months and following dose adjustments

Common side effects (typically emerge within first few weeks and often resolve): 1

• Nausea (most common reason for discontinuation)
• Sexual dysfunction
• Headache, insomnia, dizziness
• Dry mouth, diarrhea, somnolence

Combination with Cognitive Behavioral Therapy

Combining an SSRI with individual cognitive behavioral therapy (CBT) provides superior outcomes compared to either treatment alone for moderate to severe anxiety. 1, 2

• Individual CBT is prioritized over group therapy due to superior clinical and cost-effectiveness 5, 1
• Recommended duration: 12–20 sessions over 3–4 months 1
• If face-to-face CBT is unavailable, self-help CBT with professional support is a viable alternative 5, 1

Treatment Duration and Maintenance

After achieving remission, continue medication for a minimum of 9–12 months to prevent relapse. 1

For recurrent episodes, long-term or indefinite maintenance therapy is advised to reduce relapse risk. 1

What to Avoid

Benzodiazepines should NOT be used as first-line therapy: 1, 2

• Reserve only for short-term use (days to a few weeks) due to risks of dependence, tolerance, cognitive impairment, and withdrawal
• Not appropriate for long-term anxiety management

Beta-blockers (propranolol, atenolol) are deprecated for generalized anxiety disorder and social anxiety disorder based on negative evidence. 1

Tricyclic antidepressants should be avoided due to unfavorable risk-benefit profile, particularly cardiac toxicity. 1

Algorithm for Treatment Failure

If inadequate response after 8–12 weeks at therapeutic doses: 1

1. First step: Switch to a different SSRI (e.g., sertraline to escitalopram or vice versa)
2. Second step: Switch to an SNRI (venlafaxine or duloxetine)
3. Throughout: Add or intensify individual CBT if not already implemented

Common Clinical Pitfalls to Avoid

• Never discontinue SSRIs abruptly—taper gradually over 10–14 days to avoid discontinuation syndrome (dizziness, paresthesias, anxiety, irritability) 1
• Do not escalate doses too quickly—allow 1–2 weeks between increases to assess tolerability and avoid overshooting the therapeutic window 1
• Do not use gabapentin or pregabalin as first-line monotherapy—these are reserved for cases where multiple SSRI/SNRI trials have failed, particularly with comorbid pain 1, 6
• Screen for bipolar disorder before initiating SSRI therapy to avoid precipitating mania 3